Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer

Current Gerontology and Geriatrics Research

Volumn 2014, Issue , 2014, Pages

  Taverna, Gianluigi ^a   Seveso, Mauro ^a   Giusti, Guido ^a   Hurle, Rodolfo ^a   Graziotti, Pierpaolo ^a   Štifter, Sanja ^b   Chiriva Internati, Maurizio ^c   Grizzi, Fabio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF RIJEKA   (Croatia)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897537930     PISSN: 16877063     EISSN: 16877071     Source Type: Journal    
DOI: 10.1155/2014/478126     Document Type: Review

References (130)

1. Siegel R., DeSantis C., Virgo K., Cancer treatment and survivorship statistics. CA. A Cancer Journal for Clinicians 2012 62 4 220 241
2. Leitzmann M. F., Rohrmann S., Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clinical Epidemiology 2012 4 1 1 11 2-s2.0-84856781182 10.2147/CLEP.S16747
3. Daly T., Hickey B. E., Lehman M., Francis D. P., See A. M., Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database of Systematic Reviews 2011 12 CD007234 2-s2.0-84856250517
4. Moskovic D. J., Miles B. J., Lipshultz L. I., Khera M., Emerging concepts in erectile preservation following radical prostatectomy: a guide for clinicians. International Journal of Impotence Research 2011 23 5 181 192 2-s2.0-80052719266 10.1038/ijir.2011.26
5. Lawrentschuk N., Trottier G., Kuk C., Zlotta A. R., Role of surgery in high-risk localized prostate cancer. Current Oncology 2010 17 supplement 2 S25 S32 2-s2.0-78149443866
6. Miyake H., Fujisawa M., Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches. International Journal of Urology 2012 20 3 301 311
7. Lumen N., Fonteyne V., de Meerleer G., de Visschere P., Ost P., Oosterlinck W., Villeirs G., Screening and early diagnosis of prostate cancer: an update. Acta Clinica Belgica 2012 67 4 270 275
8. Carlsson S., Vickers A. J., Roobol M., Eastham J., Scardino P., Lilja H., Hugosson J., Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. Journal of Clinical Oncology 2012 30 21 2581 2584
9. Eylert M. F., Persad R., Management of prostate cancer. British Journal of Hospital Medicine 2012 73 2 95 99 2-s2.0-84857883125
10. Spahn M., Haeni K., Approach to prostate cancer in men older than 75 years: active or passive? Urologe A 2012 51 10 1368 1374
11. Kessler E. R., Flaig T. W., Optimal management of recurrent prostate cancer in older patients. Drugs Aging 2012 29 11 871 883
12. Albrand G., Mottet N., Ruffion A., Flechon A., Bensadoun R. J., Gigante M., Guy L., Mongiat-Artus P., Prostate cancer in elderly subjects: how diagnosis should be made, why and how geriatric assessment should be implemented. Progrès en Urologie 2012 22 supplement 2 S55 S63
13. Lee C. H., Akin-Olugbade O., Kirschenbaum A., Overview of prostate anatomy, histology, and pathology. Endocrinology and Metabolism Clinics of North America 2011 40 3 565 575 2-s2.0-80052212356 10.1016/j.ecl.2011.05.012
14. Orsted D. D., Bojesen S. E., The link between benign prostatic hyperplasia and prostate cancer. Nature Reviews Urology 2012 10 1 49 54
15. Mackinnon A. C., Yan B. C., Joseph L. J., Al-Ahmadie H. A., Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Archives of Pathology and Laboratory Medicine 2009 133 7 1033 1040 2-s2.0-67649805085
16. Liu W., Laitinen S., Khan S., Vihinen M., Kowalski J., Yu G., Chen L., Ewing C. M., Eisenberger M. A., Carducci M. A., Nelson W. G., Yegnasubramanian S., Luo J., Wang Y., Xu J., Isaacs W. B., Visakorpi T., Bova G. S., Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature Medicine 2009 15 5 559 565 2-s2.0-67349257845 10.1038/nm.1944
17. Aschelter A. M., Giacinti S., Caporello P., Marchetti P., Genomic and epigenomic alterations in prostate cancer. Frontiers in Endocrinology 2012 3, article 128
18. Holcomb I. N., Young J. M., Coleman I. M., Salari K., Grove D. I., Li H., True L. D., Roudier M. P., Morrissey C. M., Higano C. S., Nelson P. S., Vessella R. L., Trask B. J., Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Research 2009 69 19 7793 7802 2-s2.0-70350223620 10.1158/0008-5472.CAN-08-3810
19. Tomlins S. A., Rhodes D. R., Perner S., Dhanasekaran S. M., Mehra R., Sun X., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J. E., Shah R. B., Pienta K. J., Rubin M. A., Chinnaiyan A. M., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005 310 5748 644 648 2-s2.0-27344451557 10.1126/science.1117679 (Pubitemid 41528150)
20. Nakagawa H., Akamatsu S., Takata R., Takahashi A., Kubo M., Nakamura Y., Prostate cancer genomics, biology, and risk assessment through genome-wide association studies. Cancer Science 2012 103 4 607 613 2-s2.0-84859005156 10.1111/j.1349-7006.2011.02193.x
21. Cazares L. H., Drake R. R., Esquela-Kirscher A., Lance R. S., Semmes O. J., Troyer D. A., Molecular pathology of prostate cancer. Cancer Biomarkers 2010 9 1-6 441 459 2-s2.0-82955250046
22. van Neste L., Herman J. G., Otto G., Bigley J. W., Epstein J. I., van Criekinge W., The epigenetic promise for prostate cancer diagnosis. The Prostate 2012 72 11 1248 1261 2-s2.0-82755167771 10.1002/pros.22459
23. Chen R., Ren S., Meng T., Aguilar J., Sun Y., Impact of glutathione-S-transferases (GST) polymorphisms and hypermethylation of relevant genes on risk of prostate cancer biochemical recurrence: a meta-analysis. PLoS ONE 2013 8 9 e74775
24. Richiardi L., Fiano V., Grasso C., Zugna D., Delsedime L., Gillio-Tos A., Merletti F., Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate Ccncer. PLoS ONE 2013 8 7 e68162
25. Wilt T. J., Brawer M. K., Jones K. M., Radical prostatectomy versus observation for localized prostate cancer. The New England Journal of Medicine 2012 367 3 203 213
26. Barbieri C. E., Demichelis F., Rubin M. A., Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology 2012 60 1 187 198 2-s2.0-84255199166 10.1111/j.1365-2559.2011.04041.x
27. Cheng L., Montironi R., Bostwick D. G., Lopez-Beltran A., Berney D. M., Staging of prostate cancer. Histopathology 2012 60 1 87 117 2-s2.0-84255178364 10.1111/j.1365-2559.2011.04025.x
28. Luo J., Solimini N. L., Elledge S. J., Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009 136 5 823 837 2-s2.0-61449182121 10.1016/j.cell.2009.02.024
29. Sun J., Turner A., Xu J., Grönberg H., Isaacs W., Genetic variability in inflammation pathways and prostate cancer risk. Urologic Oncology: Seminars and Original Investigations 2007 25 3 250 259 2-s2.0-34247646625 10.1016/j.urolonc.2006.10.001 (Pubitemid 46670748)
30. Foye A., Febbo P. G., Cancer gene profiling in prostate cancer. Methods in Molecular Biology 2010 576 293 326 2-s2.0-74049087927
31. Golias C., Charalabopoulos A., Stagikas D., Giannakopoulos X., Peschos D., Batistatou A., Sofikitis N., Charalabopoulos K., Molecular profiling and genomic microarrays in prostate cancer. Experimental Oncology 2007 29 2 82 84 2-s2.0-34548180608 (Pubitemid 47310499)
32. Konishi N., Shimada K., Ishida E., Nakamura M., Molecular pathology of prostate cancer. Pathology International 2005 55 9 531 539 2-s2.0-27144470528 10.1111/j.1440-1827.2005.01865.x (Pubitemid 41725526)
33. Reynolds M. A., Molecular alterations in prostate cancer. Cancer Letters 2008 271 1 13 24 2-s2.0-53049107356 10.1016/j.canlet.2008.04.047
34. Yates C., Prostate tumor cell plasticity: a consequence of the microenvironment. Advances in Experimental Medicine and Biology 2011 720 81 90 2-s2.0-80053920605 10.1007/978-1-4614-0254-1-7
35. Franco O. E., Hayward S. W., Targeting the tumor stroma as a novel therapeutic approach for prostate cancer. Advances in Pharmacology 2012 65 267 313
36. Barron D. A., Rowley D. R., The reactive stroma microenvironment and prostate cancer progression. Endocrine-Related Cancer 2012 19 6 R187 R204
37. Iacopino F., Angelucci C., Sica G., Interactions between normal human fibroblasts and human prostate cancer cells in a co-culture system. Anticancer Research 2012 32 5 1579 1588
38. Parrinello S., Coppe J., Krtolica A., Campisi J., Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. Journal of Cell Science 2005 118 part 3 485 496 2-s2.0-13944260728 10.1242/jcs.01635 (Pubitemid 40310116)
39. Goldstein A. S., Witte O. N., Does the microenvironment influence the cell types of origin for prostate cancer? Genes and Development 2013 27 14 1539 1544
40. Gharaee-Kermani M., Kasina S., Moore B. B., Thomas D., Mehra R., Macoska J. A., CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS ONE 2012 7 11 e49278
41. Singer E., Linehan J., Babilonia G., Imam S. A., Smith D., Loera S., Wilson T., Smith S., Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia. PLoS ONE 2013 8 6 e60562
42. Jia Z., Rahmatpanah F. B., Chen X., Lernhardt W., Wang Y., Xia X. Q., Sawyers A., Sutton M., McClelland M., Mercola D., Expression changes in the stroma of prostate cancer predict subsequent relapse. PLoS ONE 2012 7 8 e41371
43. Jia Z., Wang Y., Sawyers A., Yao H., Rahmatpanah F., Xia O., Xu Q., Pio R., Turan T., Koziol J. A., Goodison S., Carpenter P., Wang-Rodriguez J., Simoneau A., Meyskens F., Sutton M., Lernhardt W., Beach T., Monforte J., McClelland M., Mercola D., Diagnosis of prostate cancer using differentially expressed genes in stroma. Cancer Research 2011 71 7 2476 2487 2-s2.0-79953309070 10.1158/0008-5472.CAN-10-2585
44. Reinertsen T., Halgunset J., Viset T., Flatberg A., Haugsmoen L. L., Skogseth H., Gene expressional changes in prostate fibroblasts from cancerous tissue. APMIS 2012 120 7 558 571 2-s2.0-84856106532 10.1111/j.1600-0463.2011. 02865.x
45. Vykhovanets E. V., MacLennan G. T., Vykhovanets O. V., Gupta S., IL-17 expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients. International Journal of Clinical and Experimental Pathology 2011 4 6 552 565 2-s2.0-80055037636
46. Fang L. Y., Izumi K., Lai K. P., Liang L., Li L., Miyamoto H., Lin W. J., Chang C., Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Research 2013 73 18 5633 5646
47. Okada K., Kojima M., Naya Y., Kamoi K., Yokoyama K., Takamatsu T., Miki T., Correlation of histological inflammation in needle biopsy specimens with serum prostate- specific antigen levels in men with negative biopsy for prostate cancer. Urology 2000 55 6 892 898 2-s2.0-0034027783 10.1016/S0090-4295(00) 00519-7 (Pubitemid 30330795)
48. Pittoni P., Colombo M. P., The dark side of mast cell-targeted therapy in prostate cancer. Cancer Research 2012 72 4 831 835 2-s2.0-84857201114 10.1158/0008-5472.CAN-11-3110
49. - NK cell subset with specificity for pancreatic and prostate cancer cell lines. Cancer Immunology, Immunotherapy 2010 59 12 1757 1769 2-s2.0-77957681199 10.1007/s00262-010-0897-y
50. Kryvenko O. N., Jankowski M., Chitale D. A., Tang D., Rundle A., Trudeau S., Rybicki B. A., Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Modern Pathology 2012 25 7 1023 1032 2-s2.0-84858977209 10.1038/modpathol.2012.51
51. Sfanos K. S., de Marzo A. M., Prostate cancer and inflammation: the evidence. Histopathology 2012 60 1 199 215 2-s2.0-84255204457 10.1111/j.1365-2559.2011.04033.x
52. Flammiger A., Bayer F., Cirugeda-Kuhnert A., Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS 2012 120 11 901 908
53. McDowell K. L., Begley L. A., Mor-Vaknin N., Markovitz D. M., Macoska J. A., Leukocytic promotion of prostate cellular proliferation. The Prostate 2010 70 4 377 389 2-s2.0-76149104586 10.1002/pros.21071
54. Liu Y., Saeter T., Vlatkovic L., Servoll E., Waaler G., Axcrona U., Giercksky K. E., Nesland J. M., Suo Z. H., Axcrona K., Dendritic and lymphocytic cell infiltration in prostate carcinoma. Histology and Histopathology 2013 28 12 1621 1628
55. Lakshmi Narendra B., Eshvendar Reddy K., Shantikumar S., Ramakrishna S., Immune system: a double-edged sword in cancer. Inflammation Research 2013 62 9 823 834
56. Albertsen P. C., Hanley J. A., Fine J., 20-year outcomes following conservative management of clinically localized prostate cancer. Journal of the American Medical Association 2005 293 17 2095 2101 2-s2.0-17844402699 10.1001/jama.293.17.2095 (Pubitemid 40617061)
57. Lu-Yao G. L., Albertsen P. C., Moore D. F., Shih W., Lin Y., DiPaola R. S., Barry M. J., Zietman A., O'Leary M., Walker-Corkery E., Yao S., Outcomes of localized prostate cancer following conservative management. Journal of the American Medical Association 2009 302 11 1202 1209 2-s2.0-70349140531 10.1001/jama.2009.1348
58. Shappley W. V. III, Kenfield S. A., Kasperzyk J. L., Qiu W., Stampfer M. J., Sanda M. G., Chan J. M., Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. Journal of Clinical Oncology 2009 27 30 4980 4985 2-s2.0-75449094075 10.1200/JCO.2008.21.2613
59. Froehner M., Wirth M. P., Locally advanced prostate cancer: optimal therapy in older patients. Drugs Aging 2013 30 12 959 967
60. Jenny N. S., Inflammation in aging: cause, effect, or both? Discovery Medicine 2012 13 73 451 460
61. Taylor R. C., Dillin A., Aging as an event of proteostasis collapse. Cold Spring Harbor perspectives in biology 2011 3 5 2-s2.0-80052532648 10.1101/cshperspect.a004440
62. Nystrom T., Yang J., Molin M., Peroxiredoxins, gerontogenes linking aging to genome instability and cancer. Genes and Development 2012 26 18 2001 2008
63. Sahin E., Depinho R. A., Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010 464 7288 520 528 2-s2.0-77950265945 10.1038/nature08982
64. Seo A. Y., Joseph A., Dutta D., Hwang J. C. Y., Aris J. P., Leeuwenburgh C., New insights into the role of mitochondria in aging: mitochondrial dynamics and more. Journal of Cell Science 2010 123 15 2533 2542 2-s2.0-77955351652 10.1242/jcs.070490
65. Freund A., Orjalo A. V., Desprez P., Campisi J., Inflammatory networks during cellular senescence: causes and consequences. Trends in Molecular Medicine 2010 16 5 238 246 2-s2.0-77952105389 10.1016/j.molmed.2010.03.003
66. Benelli R., Stigliani S., Minghelli S., Carlone S., Ferrari N., Impact of CXCL1 overexpression on growth and invasion of prostate cancer cell. The Prostate 2013 73 9 941 951
67. Bonecchi R., Locati M., Mantovani A., Chemokines and cancer: a fatal attraction. Cancer Cell 2011 19 4 434 435 2-s2.0-79953750882 10.1016/j.ccr.2011.03.017
68. Bianchi-Frias D., Vakar-Lopez F., Coleman I. M., Plymate S. R., Reed M. J., Nelson P. S., The effects of aging on the molecular and cellular composition of the prostate microenvironment. PLoS ONE 2010 5 9 2-s2.0-77958580732 10.1371/journal.pone.0012501 e12501
69. Straub R. H., Miller L. E., Schölmerich J., Zietz B., Cytokines and hormones as possible links between endocrinosenescence and immunosenescence. Journal of Neuroimmunology 2000 109 1 10 15 2-s2.0-0034283784 10.1016/S0165-5728(00)00296-4
70. Lang P. O., Govind S., Aspinall R., Reversing T cell immunosenescence: why, who, and how. Age 2012 35 3 609 620 2-s2.0-84857241663 10.1007/s11357-012- 9393-y
71. Franceschi C., Bonafè M., Valensin S., Olivieri F., de Luca M., Ottaviani E., de Benedictis G., Inflamm-aging. An evolutionary perspective on immunosenescence. Annals of the New York Academy of Sciences 2000 908 244 254 2-s2.0-0033911488 (Pubitemid 30462008)
72. McElhaney J. E., Effros R. B., Immunosenescence: what does it mean to health outcomes in older adults? Current Opinion in Immunology 2009 21 4 418 424 2-s2.0-68149179573 10.1016/j.coi.2009.05.023
73. Campisi J., Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005 120 4 513 522 2-s2.0-13944270339 10.1016/j.cell.2005.02.003 (Pubitemid 40269765)
74. Goronzy J. J., Weyand C. M., Immune aging and autoimmunity. Cellular and Molecular Life Sciences 2012 69 10 1615 1623 2-s2.0-84858956399 10.1007/s00018-012-0970-0
75. Malaguarnera L., Cristaldi E., Malaguarnera M., The role of immunity in elderly cancer. Critical Reviews in Oncology/Hematology 2010 74 1 40 60 2-s2.0-77249088142 10.1016/j.critrevonc.2009.06.002
76. Zhang S. J., Qian H. N., Zhao Y., Sun K., Wang H. Q., Liang G. Q., Li F. H., Li Z., Relationship between age and prostate size. Asian Journal of Andrology 2013 15 1 116 120
77. Turkbey B., Huang R., Vourganti S., Trivedi H., Bernardo M., Yan P., Benjamin C., Pinto P. A., Choyke P. L., Age-related changes in prostate zonal volumes as measured by high-resolution magnetic resonance imaging (MRI): a cross-sectional study in over 500 patients. BJU International 2012 110 11 1642 1647
78. Das A., Bortner J. D. Jr., Aliaga C. A., Baker A., Stanley A., Stanley B. A., Kaag M., Richie J. P. Jr., El-Bayoumy K., Changes in proteomic profiles in different prostate lobes of male rats throughout growth and development and aging stages of the life span. The Prostate 2012 73 4 363 375
79. Migita T., Inoue S., Implications of the Golgi apparatus in prostate cancer. The International Journal of Biochemistry and Cell Biology 2012 44 11 1872 1876
80. Richie J. P. Jr., Das A., Calcagnotto A. M., Aliaga C. A., El-Bayoumy K., Age related changes in selenium and glutathione levels in different lobes of the rat prostate. Experimental Gerontology 2012 47 3 223 228 2-s2.0-84857061115 10.1016/j.exger.2011.11.015
81. Wilson J. D., The critical role of androgens in prostate development. Endocrinology and Metabolism Clinics of North America 2011 40 3 577 590 2-s2.0-80052229450 10.1016/j.ecl.2011.05.003
82. Montico F., Hetzl A. C., Cândido E. M., Fávaro W. J., Cagnon V. H. A., Hormonal therapy in the senescence: prostatic microenvironment structure and adhesion molecules. Micron 2011 42 6 642 655 2-s2.0-79955639888 10.1016/j.micron.2011.03.004
83. Pierorazio P. M., Ferrucci L., Kettermann A., Longo D. L., Metter E. J., Carter H. B., Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU International 2010 105 6 824 829 2-s2.0-77649247662 10.1111/j.1464-410X.2009. 08853.x
84. Wynn T. A., Chawla A., Pollard J. W., Macrophage biology in development, homeostasis and disease. Nature 2013 496 7446 445 455
85. Biswas S. K., Allavena P., Mantovani A., Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Seminars in Immunopathology 2013 35 5 585 600
86. Biswas S. K., Mantovani A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology 2010 11 10 889 896 2-s2.0-77956976681 10.1038/ni.1937
87. Mantovani A., Sica A., Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Current Opinion in Immunology 2010 22 2 231 237 2-s2.0-77950944395 10.1016/j.coi.2010.01.009
88. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M. G., Rimoldi M., Biswas S. K., Allavena P., Mantovani A., Macrophage polarization in tumour progression. Seminars in Cancer Biology 2008 18 5 349 355 2-s2.0-48349102876 10.1016/j.semcancer.2008.03.004
89. Mantovani A., Sica A., Locati M., New vistas on macrophage differentiation and activation. European Journal of Immunology 2007 37 1 14 16 2-s2.0-33846352854 10.1002/eji.200636910 (Pubitemid 46128780)
90. Rigo A., Gottardi M., Zamò A., Mauri P., Bonifacio M., Krampera M., Damiani E., Pizzolo G., Vinante F., Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Molecular Cancer 2010 9, article 273 2-s2.0-77957798181 10.1186/1476-4598-9-273
91. Li W., Phagocyte dysfunction, tissue aging and degeneration. Ageing Research Reviews 2013 12 4 1005 1012
92. Sroka I. C., Sandoval C. P., Chopra H., Gard J. M. C., Pawar S. C., Cress A. E., Macrophage-dependent cleavage of the laminin receptor α 6 β 1 in prostate cancer. Molecular Cancer Research 2011 9 10 1319 1328 2-s2.0-80054679297 10.1158/1541-7786.MCR-11-0080
93. Lissbrant I. F., Stattin P., Wikstrom P., Damber J. E., Egevad L., Bergh A., Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. International Journal of Oncology 2000 17 3 445 451 2-s2.0-0034266661
94. Lindholm P. F., Lu Y., Adley B. P., Vladislav T., Jovanovic B., Sivapurapu N., Yang X. J., Kajdacsy-Balla A., Role of monocyte-lineage cells in prostate cancer cell invasion and tissue factor expression. The Prostate 2010 70 15 1672 1682 2-s2.0-77958468844 10.1002/pros.21202
95. Richardsen E., Uglehus R. D., Due J., Busch C., Busund L.-T. R., The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Histopathology 2008 53 1 30 38 2-s2.0-45549093317 10.1111/j.1365-2559.2008. 03058.x (Pubitemid 351861980)
96. Shirotake S., Miyajima A., Kosaka T., Tanaka N., Kikuchi E., Mikami S., Okada Y., Oya M., Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. The American Journal of Pathology 2012 180 3 1008 1016 2-s2.0-84857218019 10.1016/j.ajpath.2011.11.027
97. Nonomura N., Takayama H., Kawashima A., Mukai M., Nagahara A., Nakai Y., Nakayama M., Tsujimura A., Nishimura K., Aozasa K., Okuyama A., Decreased infiltration of macrophage scavenger receptor-positive cells in initial negative biopsy specimens is correlated with positive repeat biopsies of the prostate. Cancer Science 2010 101 6 1570 1573 2-s2.0-77954155302 10.1111/j.1349-7006.2010. 01563.x
98. Shimura S., Yang G., Ebara S., Wheeler T. M., Frolov A., Thompson T. C., Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Research 2000 60 20 5857 5861 2-s2.0-0034667386
99. Gollapudi K., Galet C., Grogan T., Zhang H., Said J. W., Huang J., Elashoff D., Freedland S. J., Rettig M., Aronson W. J., Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. American Journal of Cancer Research 2013 3 5 523 529
100. de Marzo A. M., Platz E. A., Sutcliffe S., Xu J., Grönberg H., Drake C. G., Nakai Y., Isaacs W. B., Nelson W. G., Inflammation in prostate carcinogenesis. Nature Reviews Cancer 2007 7 4 256 269 2-s2.0-33947687854 10.1038/nrc2090 (Pubitemid 46486616)
101. Olumi A. F., Commentary on, "Age-related alterations in T-lymphocytes modulate key pathways in prostate tumorigenesis" A. de Angulo, R. Faris, D. Cavazos, C. Jolly, B. Daniel, L. DeGraffenried, Department of Nutritional Sciences, Dell Pediatric Research Institute, University of Texas, Austin, TX, USA.: Prostate, vol. 73, no. 8, pp. 855-864, 2013. Urologic Oncology 2014 32 2 212 213
102. de Angulo A., Faris R., Cavazos D., Jolly C., Daniel B., DeGraffenried L., Age-related alterations in T-lymphocytes modulate key pathways in prostate tumorigenesis. The Prostate 2013 73 8 855 864
103. Hussein M. A., AL-Assiri M., Musalam A. O., Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Experimental and Molecular Pathology 2009 86 2 108 113 2-s2.0-62949162336 10.1016/j.yexmp.2008.11.010
104. Celma A., Servian P., Planas J., Placer J., Quilez M. T., Arbos M. A., de Torres I., Morote J., Clinical significance of proliferative inflammatory atrophy in prostate biopsy. Actas Urologicas Espanolas 2013 38 2 122 126
105. de Nunzio C., Kramer G., Marberger M., Montironi R., Nelson W., Schröder F., Sciarra A., Tubaro A., The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. European Urology 2011 60 1 106 117 2-s2.0-79957957222 10.1016/j.eururo.2011.03. 055
106. Robert G., Descazeaud A., Nicolaïew N., Terry S., Sirab N., Vacherot F., Maillé P., Allory Y., de la Taille A., Inflammationin benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. The Prostate 2009 69 16 1774 1780 2-s2.0-70350457523 10.1002/pros.21027
107. Fujii T., Shimada K., Asai O., Tanaka N., Fujimoto K., Hirao K., Konishi N., Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. PathoBiology 2013 80 3 119 126
108. Seliger B., Stoehr R., Handke D., Mueller A., Ferrone S., Wullich B., Tannapfel A., Hofstaedter F., Hartmann A., Association of HLA class i antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunology, Immunotherapy 2010 59 4 529 540 2-s2.0-77449133036 10.1007/s00262-009-0769-5
109. Plackett T. P., Boehmer E. D., Faunce D. E., Kovacs E. J., Aging and innate immune cells. Journal of Leukocyte Biology 2004 76 2 291 299 2-s2.0-3442899305 10.1189/jlb.1103592 (Pubitemid 39006941)
110. Li J., Schuler-Thurner B., Schuler G., Huber C., Seliger B., Bipartite regulation of different components of the MHC class I antigen-processing machinery during dendritic cell maturation. International Immunology 2001 13 12 1515 1523 2-s2.0-0035214302 (Pubitemid 33133878)
111. Blades R. A., Keating P. J., McWilliam L. J., George N. J. R., Stern P. L., Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995 46 5 681 686 2-s2.0-0028818052
112. Qiu T., Wang L., Liu X. H., Weng X. D., Kuang Y. L., Chen Z. Y., Chen H., Zhu H. C., Over-expressing transporters associated with antigen processing increases antitumor immunity response in prostate cancer. Cellular Immunology 2012 279 2 167 173
113. Snyder A., Tepper J. E., Slovin S. F., Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future? Seminars in Oncology 2013 40 3 347 360
114. Michael A., Relph K., Annels N., Pandha H., Prostate cancer vaccines. Expert Review of Vaccines 2013 12 3 253 262
115. Hammerstrom A. E., Cauley D. H., Atkinson B. J., Sharma P., Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy 2011 31 8 813 828 2-s2.0-79961109805 10.1592/phco.31.8.813
116. Cheema Z., Hari-Gupta Y., Kita G. X., Farrar D., Seddon I., Corr J., Klenova E., Expression of the cancer-testis antigen BORIS correlates with prostate cancer. The Prostate 2014 74 2 164 176
117. Chiriva-Internati M., Yu Y., Mirandola L., D'Cunha N., Hardwicke F., Cannon M. J., Cobos E., Kast W. M., Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. The Prostate 2012 72 1 12 23 2-s2.0-81855194457 10.1002/pros.21400
118. Simpson A. J. G., Caballero O. L., Jungbluth A., Chen Y., Old L. J., Cancer/testis antigens, gametogenesis and cancer. Nature Reviews Cancer 2005 5 8 615 625 2-s2.0-23144464171 10.1038/nrc1669 (Pubitemid 41081387)
119. Hudolin T., Juretic A., Spagnoli G. C., Pasini J., Bandic D., Heberer M., Kosicek M., Cacic M., Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue. The Prostate 2006 66 1 13 18 2-s2.0-29344471439 10.1002/pros.20312 (Pubitemid 43005945)
120. Smith H. A., Cronk R. J., Lang J. M., McNeel D. G., Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Research 2011 71 21 6785 6795 2-s2.0-80155131086 10.1158/0008-5472.CAN-11-2127
121. Ardiani A., Farsaci B., Rogers C. J., Protter A. A., Guo Z., King T. H., Apelian D., Hodge J. W., Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clinical Cancer Research 2013 19 22 6205 6218
122. Kong H. Y., Byun J., Emerging roles of human prostatic acid phosphatase. Biomolecules and Therapeutics 2013 21 1 10 20
123. Drake C. G., Prostate cancer as a model for tumour immunotherapy. Nature Reviews Immunology 2010 10 8 580 593 2-s2.0-77954939175 10.1038/nri2817
124. Wada S., Jackson C. M., Yoshimura K., Yen H. R., Getnet D., Harris T. J., Goldberg M. V., Bruno T. C., Grosso J. F., Durham N., Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. Journal of Translational Medicine 2013 11, article 89
125. Perez S. A., Anastasopoulou E. A., Tzonis P., Gouttefangeas C., Kalbacher H., Papamichail M., Baxevanis C. N., AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. Cancer Immunology, Immunotherapy: CII 2013 62 10 1599 1608
126. Higano C. S., Potential use of custirsen to treat prostate cancer. OncoTargets and Therapy 2013 6 785 797
127. Kwon O. J., Zhang L., Ittmann M. M., Xin L., Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proceedings of the National Academy of Sciences of the United States of America 2014 111 5 1666 1667
128. Quon H., Loblaw A., Nam R., Dramatic increase in prostate cancer cases by 2021. BJU International 2011 108 11 1734 1738 2-s2.0-81255134226 10.1111/j.1464-410X.2011.10197.x
129. Shelke A. R., Mohile S. G., Treating prostate cancer in elderly men: how does aging affect the outcome? Current Treatment Options in Oncology 2011 12 3 263 275 2-s2.0-80055019663 10.1007/s11864-011-0160-6
130. Rice K. R., Colombo M. L., Wingate J., Chen Y., Cullen J., McLeod D. G., Brassell S. A., Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat. Urologic Oncology: Seminars and Original Investigations 2013 31 6 755 760 2-s2.0-80051937528 10.1016/j.urolonc.2011.07.004